The Europe biosimilar market was valued at USD 10.13 Billion in 2024, driven by expanded use in treating chronic diseases. With rising demand and cost-effective alternatives to biologics, the market is projected to grow at a CAGR of 12.80% and reach USD 33.78 Billion by 2034. https://www.expertmarketresearch.com/reports/europe-biosimilar-market